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Open access underA B S T R A C TAvailable online 21 August 2012 Hepcidin, a 25 amino-acid liver hormone, has recently emerged as the key regulator of iron
homeostasis. Proteomic studies in limited number of subjects have shown that biological
fluids can also contain truncated isoforms, whose role remains to be elucidated. We report,
for the first time, data about serum levels of the hepcidin-20 isoform (hep-20) in a general
population, taking advantage of the Val Borbera (VB) study where hepcidin-25 (hep-25) was
measured by SELDI-TOF-MS. Detectable amount of hep-20 were found in sera from 854 out
of 1577 subjects (54.2%), and its levels were about 14% of hep-25 levels. A small fraction of
subjects (n=30, 1.9%) had detectable hep-20 but undetectable hep-25. In multivariate
regression models, significant predictors of hep-20 were hep-25 and age in males, and
hep-25, age, serum ferritin and body mass index in females. Of note, the hep-25:hep-20 ratio
was not constant in the VB population, but increased progressively with increasing ferritin
levels. This is not consistent with the simplistic view of hep-20 as a mere catabolic byproduct
of hep-25. Although a possible active regulation of hep-20 production needs further
confirmation, our results may also have implications for immunoassays for serum hepcidin
based on antibodies lacking specificity for hep-25.
This article is part of a Special Issue entitled: Integrated omics.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.Keywords:
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SELDI-TOF-MS1. Introduction
In the last decade hepcidin, a small peptide hormone, has
emerged as the key regulator of systemic iron homeostasis
[1,2]. Hepcidin inhibits the intestinal absorption of dietary iron, C-reactive protein; Hep
led: Integrated omics.
icine, University of Veron
(D. Girelli).
 CC BY-NC-ND license.and the release of iron from macrophages through the inter-
action with the transmembrane iron exporter ferroportin,
causing its internalization and degradation in lysosomes [3].
The iron bioactive form of hepcidin is a 25-amino acid peptide
(hep-25) that shares high homologywith defensins, a family of-20, Hepcidin-20; Hep-24, Hepcidin-24; Hep-25, Hepcidin-25; PTH,
a, Policlinico G.B. Rossi, 37134 Verona, Italy. Tel.: +39 045 8124791;
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produced mainly by the liver as an 84-amino acid precursor
that subsequently undergoes proteolytic cleavages to generate
the mature form [5]. Further hep-25 processing can result in
the generation of two amino-terminal truncated isoforms,
hepcidin-22 (hep-22) and hepcidin-20 (hep-20), whose physi-
ological role is still unclear [6]. The development of a reliable
hepcidin assay has been proven difficult, particularly with
classical immunological methods, yielding to a number of
different approaches [7]. Among these, Mass Spectrometry (MS)
based studies in limited number of subjects have identified and
measured small amounts of hep-20 in both serum and urine,
while hep-22 has been found only in urine [8]. Of note,
functional studies have demonstrated that the two truncated
isoforms almost completely loss the ability to interact with
ferroportin [9]. Being inactive in iron regulation, they have been
postulated to be degradation byproducts of hep-25. On the other
hand, recent studies have suggested that hep-20 may retain
greater antimicrobial and fungicidal activity than hep-25,
particularly at acidic pH (pH 5.0) [10,11]. In the small series
published until now, relatively high levels of hep-20 have been
detected in heterogeneous pathological conditions like acute
myocardial infarction (AMI) [12], anemia of chronic disease
(ACD) [13], and, particularly, in chronic kidney disease (CKD)
[14–16]. In our previous study using an improved Surface
Enhanced Laser Desorption/Ionization Time of Flight-MS
(SELDI-TOF-MS) approach where 54 patients in chronic hemo-
dialysis were comparedwith 57 controls, hep-20was detectable
in 100% and 39%, respectively [15]. Kroot et al. [17] evaluated 186
patients with various diseases and 23 healthy controls by a
weak cation exchange (WCX)-TOF-MS assay. No isoforms werehepcidin-20
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Fig. 1 – Representative SELDI-TOF-MS profile of serum samples f
internal standard. The hepcidin isoforms hep-20, hep-24 (synthefound in sera from healthy subjects and patients with low
hepcidin concentrations, while relevant amount of hep-20were
found in some conditions, again particularly in CKD. These
studies highlighted that the contribution of hep-20 to “total”
serumhepcidinmeasured by a non-selective ELISA assay is not
constant but may vary substantially between healthy subjects
and patients with different diseases. However, large-scale
information about serum hep-20 concentration is lacking.
Thus, the present study was aimed at quantifying serum
hep-20 within the framework of the recently completed Iron
Section of theVal Borbera (VB) study [18], where serumhepcidin
wasmeasured by SELDI-TOF-MS. To the best of our knowledge,
we report here for the first time in a large general population the
levels of hep-20 according to age and sex, their determinants,
and the variations of hep-25:hep-20 ratio according to the iron
status.2. Material and methods
2.1. Subjects and biochemical analyses
This study included 1577 subjects aged 18–98 years enrolled in
the Iron Section of the VB study. Details about the general
design of this study, as well as the enrollment criteria have
been extensively reported elsewhere [18,19]. The study was
approved by the San Raffaele Hospital and Regione Piemonte
ethical committees, and all subjects gave written informed
consent. For each participant, anthropometric, complete blood
cell count, and biochemical parameters including serum iron,
transferrin, transferrin saturation, ferritin, creatinine, andhepcidin-24 hepcidin-25
/z
00 2750 3000
rom Val Borbera cohort with (A) and without (B) hep-24
tic analogue), and hep-25 are indicated by rectangles.
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isoforms were determined using a SELDI-TOF-MS assay
previously used for their identification and characterization
[8], and subsequently validated for quantification by several
investigators including our group [12–18,20]. Briefly, copper
loaded immobilized metal affinity capture ProteinChip arrays
(IMAC-30 Cu2+) were selected as chromatographic surface. A
synthetic hepcidin analogue, hepcidin-24 (hep-24, purchased
from Peptide International, Louisville, KY), was used as
internal standard for quantification. Spectra were collected in
duplicate for each serum samples, with or without spiking of
the internal standard at a concentration of 10 nM (Fig. 1). With
respect to hep-20 quantification, we used as reference peak
hep-20 kindly provided by Dr. Elizabeta Nemeth (University
of California Los Angeles, CA). Hep-20 concentration was
expressed in nM resulting from the following equation:
(sample 2192 m/z peak intensity)×10 nM/(hep-24 spiked sam-
ple 2673 m/z peak intensity–nonspiked sample 2673 m/z peak
intensity). Based on the measured background noise in MS
spectra, the lower limit of detection (LLOD) for both hepcidin
isoforms was 0.55 nM. It was calculated on 20 randomly
selected VB sera, and was in agreement with the LLOD
previously published by our group and others [20]. Adequate
linear standard curve (y=1.566×−0.254, R2=0.998) was obtained
by serially diluting synthetic hepcidin-20 in blank serum
(diluted 1:100 in water). Intra-day precision was determined by
using three different concentrations of hep-20 (5, 10, and
25 nM), each with seven replicates. This was repeated on four
separate days. Precisionwas assessed by coefficient of variation
(CV%). The within- and between run precisions at the low
concentrations similar to what found in VB subjects were
6.9% and 7.0%, respectively. The mean peak intensity ratio
hepcidin-24/hepcidin-20 in blank serum spiked with both
peptides at 7 different concentration combinations (25, 20, 15,
12.5, 10, 7.5, and 5 nM) was 0.85, i.e. similar to what obtained for
the main isoform hepcidin-25 [15].Table 1 –Main characteristics of the total population.
Total population
N=1577
Age (years) 55.7±17.8
BMI 25.9±4.4
s-iron (μg/dl) 97.58±34.11
Transferrin (mg/dl) 242.04±41.52
Transferrin Saturation % 29.30±11.62
Ferritin a (ng/ml) 69 (65–72)
Hb (g/dl) 14.4±1.4
CRP a (mg/l) 0.17 (0.16–0.18)
Creatinine a (μmol/l) 0.85 (0.84–0.86)
Hep-20 a (nmol/l) b 0.69 (0.63–0.75)
Hep-20 a (nmol/l) c 3.31 (3.17–3.46)
Hep-20 detectable % 54.2
Hep-25 a (nmol/l) b 4.96 (4.59–5.35)
Hep-25 a (nmol/l) c 7.86 (7.54–8.19)
Hep-25 detectable % 89.1
a Variables not normally distributed are expressed as geometric means w
b Geometric mean of hep-20 and hep-25 with 95% CIs calculated on who
c Geometric mean of hep-20 and hep-25 with 95% CIs calculated on subjec2.2. Statistical analyses
Statistical analyses were performed using SPSS 17.0 software
(SPSS Inc., Chicago, IL, USA). Continuous variables were ex-
pressed as means±standard deviations, while those with a
skewed distribution, including hep-25, hep-20, hep-25:hep-20
ratio, ferritin, CRP and creatinine, were log-transformed and
expressed as geometric means with 95% confidence intervals
(CIs). Considering that in many subjects the levels of hepcidin
(in particular those of hep-20) were not detectable, not allowing
a correct log-transformation, the relative statistical analyses in
thewhole study populationwere performed adding the value of
0.1 to each hepcidin value and considering not detectable
hepcidin levels as 0 (thus, the log transformable 0.1 [0+0.1] for
statistical analysis). For sake of completeness, the analyses on
hep-25 and hep-20 were performed also in the subgroups with
detectable levels. On the other hand, the analyses on hep-25:
hep-20 ratio were performed only in subjects with detectable
levels of both isoforms. Quantitative data were analyzed using
the Student's t test or by analysis of variance (ANOVA) with
polynomial contrasts for linear trend when indicated. Sex
specific correlations between quantitative variables were
assessed using Pearson's test. Qualitative data were analyzed
using the chi-square test, with analysis for linear trend when
indicated. Independent determinants of serum hep-20 and
hep-25:hep-20 ratio were estimated by means of linear regres-
sion models, including all the variables significantly associated
at univariate analysis. Two-sides P values<0.05were considered
statistically significant.3. Results
The main characteristics of the total population are listed in
Table 1. This table also lists data stratified by gender, since we
previously observed significant gender differences in serumMales
N=706
Females
N=871
P
55.3±17.6 56.0±18.1 0.436
26.5±3.8 25.5±4.8 <0.001
105.83±36.15 90.86±30.80 <0.001
235.97±36.89 246.98±44.34 <0.001
32.30±12.11 26.85±10.60 <0.001
120 (114–128) 44 (41–47) <0.001
15.4±1.2 13.7±1.1 <0.001
0.16 (0.15–0.17) 0.17 (0.16–0.18) 0.220
0.96 (0.95–0.98) 0.77 (0.76–0.78) <0.001
0.82 (0.72–0.94) 0.60 (0.53–0.67) <0.001
3.26 (3.06–3.47) 3.35 (3.16–3.56) 0.530
59.1 50.2 –
7.09 (6.46–7.78) 3.71 (3.31–4.16) <0.001
8.89 (8.38–9.44) 7.02 (6.63–7.44) <0.001
94.6 84.6 –
ith 95% CIs.
le population (1577 subjects).
ts with detectable hepcidin levels i.e. n=854 and n=1405 respectively.
Table 2 – Sex specific correlation analysis of hepcidin-20.
Males Females
Correlation P Correlation P
Hep-25 (nmol/l) 0.480 <0.001 0.449 <0.001
Age (years) 0.096 0.049 0.178 <0.001
BMI 0.049 0.315 0.186 <0.001
s-iron (μg/dl) −0.028 0.571 −0.023 0.627
Transferrin (mg/dl) −0.039 0.430 −0.049 0.308
Transferrin
saturation %
−0.005 0.912 −0.013 0.789
Ferritin a (ng/ml) 0.062 0.206 0.149 0.002
Hb (g/dl) −0.110 0.024 −0.048 0.320
CRPa (mg/l) 0.115 0.052 0.173 0.002
Creatininea (μmol/l) −0.028 0.583 0.109 0.029
Values in bold are those considered statistically significant (P<0.05).
a Variables not normally distributed are expressed as geometric
means with 95% CIs.
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elsewhere [18]. Briefly recapitulating, hep-25 was significantly
lower in women aged <50 years as compared to men of same
age, while after this time-point (nearly corresponding to
women's menopause) hep-25 levels tended to be similar in
both sexes and relatively stable over the following decades. This
reflected mainly the lower iron status (i.e. lower ferritin levels)
of women during the fertile period, where iron absorption from
the gut needs to be allowed by low hep-25 to counterbalance
iron losses with menses. Hep-20 was detectable in 854 out of
1577 (54.2%) subjects, at variance with hep-25, which was
detectable in 89.1% of subjects. The main characteristics of the
subjects stratified for detectable serum hepcidin isoform are
reported in Supplementary Table 1. Of note, there was a group,
albeit small (n=30, 1.9%), of subjects in whom only the “minor”
hep-20 isoform was detectable. In general, as compared with
subjects with undetectable hep-20, subjects with detectable
hep-20 were older and had higher body iron status (as reflected
by transferrin saturation and ferritin levels) and hep-25 levels
(Supplementary Table 2).
The two hepcidin isoforms were significantly and positively
correlated in both sexes (males: r=0.48, P<0.001; females: r=
0.45, P<0.001; Fig. 2). At univariate analyses, hep-20 also
significantly correlated with age, hemoglobin, and C-Reactive
Protein (CRP) in men, and with age, body mass index (BMI),
ferritin, CRP and creatinine in women (Table 2). Multivariate
linear regression models showed hep-25 and age as indepen-
dent significant predictors of hep-20 inmen, while hep-25, age,
BMI, and ferritinwere significant predictors of hep-20 inwomen
(Table 3A and B). Of note, the beta coefficient of ferritin
in women was negative (Table 3B). Fig. 3A and B shows
the variations of hep-20 in the VB population according to
different ranges of age and iron status (reflected by serum
ferritin levels), respectively. In addition, Supplementary Fig. 1
shows the corresponding hep-25 levels after stratification forMales: r = 0.48; p< 0.001
Females: r = 0.45; p< 0.001
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Fig. 2 – Correlation plot between hep-20 and hep-25
(logarithmic scale).ferritin levels. We then focused on the ratio between the two
isoforms, and particularly on its behavior in relation with age
and iron parameters of VB subject (Table 4 and 5). This analysis
could be properly done only in subjects with both the hepcidin
isoforms detectable (n=824). The hep-25:hep-20 ratio was
clearly lower in women aged <50 years (i.e. premenopausal) as
compared to men of corresponding age, while differences
attenuated in the subsequent decades (Fig. 4A). Of note, the
hep-25:hep-20 ratio was not constant in the VB population, but
increased progressively according to increasing ferritin levels
(Fig. 4B). Fig. 5A and B summarizes the relative percentages of
hep-25 and hep-20 according to increasing ferritin levels. In
both sexes, the relative percentage of hep-20 progressively and
significantly decreased with increased ferritin levels.4. Discussion
Although much is known on the mechanism of action of
hepcidin through the binding with its receptor/cellular
exporter ferroportin [3], the mechanism(s) of hepcidinTable 3 – Predictors of Hep-20 levels in males (A) and
females (B).
A
Males
β-coefficient P
Hepcidin25 (nmol/l) 0.627 <0.001
Age (years) 0.126 0.007
B
Females
β-coefficient P
Hepcidin25 (nmol/l) 0.553 <0.001
Age (years) 0.177 0.004
Ferritin (μg/l) −0.255 0.001
BMI 0.163 0.003
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Age (years)
Males
Females
Males
Females
* p < 0.001 for both genders
* p < 0.001 for both genders
Hep-20 (nmol/l) Males 0.73
(0.45-0.85)
0.65 
(0.44-0.94)
0.58
(0.41-0.82)
0.63 
(0.47-0.84)
1.09 
(0.81-1.48)
0.96 
(0.67-1.36)
1.59
(1.03-2.44)
Hep-20 (nmol/l)Females 0.36 
(0.25-0.52)
0.36
(0.26-0.48)
0.42
(0.30-0.57)
0.63
(0.47-0.85)
0.84
(0.64-1.09)
0.97
(0.70-1.34)
0.62
(0.41-0.92)
*by ANOVA with polynomial contrasts for linear trend
<30 30-50 50-150 150-250 >250 Ferritin (ng/ml)
Hep-20 (nmol/l) Males 0.31
(0.18-0.52)
0.43 
(0.24-0.78)
0.73
(0.61-0.89)
1.17 
(0.90-1.53)
1.08 
(0.77-1.51)
Hep-20 (nmol/l) Females 0.33
(0.27-0.40)
0.54
(0.41-0.71)
0.85
(0.70-1.03)
1.20
(0.77-1.87)
2.11
(0.68-6.53)
*by ANOVA with polynomial contrasts for linear trend
A
B
Fig. 3 – Behavior of hep-20 in VB population according to different ranges of age (A) and ferritin (B), respectively. Males are
indicated by continuous blue line, females by a red dotted line.
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dated. Initial efforts to establish reliable assays for this
hormone have indicated that the entire pre-pro-hormone (84
amino acid) is also present in the circulation [21], while, at
variance with hep-25, its concentration correlates poorly with
iron status [22]. Moreover, small studies by MS-based tech-
niques [7,8] have found that two further N-terminal truncated
isoforms, namely hep-22 and hep-20, are present in biological
fluids, particularly hep-20 in certain disease conditions like CKD
[15,17]. Even though hep-20 may be either quantitatively or
qualitatively the most relevant isoform of “mature” hepcidin,
no large-scale population studyhas been conducted so far on its
serum levels relative to hep-25, as well as on its possible
determinants. This study establishes for the first time that
more than half individuals at population level have detectable
amount of hep-20 in the circulation. These individuals were
generally included among thosewith discrete amount of serumhep-25, who in turn represented approximately 89% of the total
VB population. As described in detail elsewhere [18], the
remaining 11% of individuals were mostly represented by
pre-menopausal women with highly prevalent low iron status
[23], implying the need to suppress hepcidin for up-regulating
the absorption of dietary iron [2]. The large VB database also
allowed us to investigate the relevant variables associated with
hep-20 levels. To put our results into perspective, we will
discuss inmore detail twomain possible practical implications.
4.1. Hepcidin-20 as a possible caveat in hepcidin assay for
clinical purpose
To the best of our knowledge, the VB is the first large-scale
population study on serum hepcidin using a MS-based assay.
The high correlation of hep-25 with iron status was reported
elsewhere [18], and paralleled what observed in a Dutch
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A
B
Fig. 4 – Hep-25:hep-20 ratio in groups of individuals
classified according to age (A) and ferritin levels (B),
respectively. Males are indicated by blue continuous line,
females by a red dotted line.
Table 4 – Sex specific correlation analysis of hep-25:
hep-20 ratio.
Males Females
Correlation P Correlation P
Age (years) −0.119 0.015 0.136 0.006
BMI −0.027 0.588 0.073 0.137
s-iron (μg/dl) 0.098 0.046 0.118 0.016
Transferrin (mg/dl) −0.074 0.135 −0.193 <0.001
Transferrin
saturation %
0.106 0.032 0.172 <0.001
Ferritin a (ng/ml) 0.497 <0.001 0.564 <0.001
Hb (g/dl) −0.009 0.850 0.134 0.006
CRPa (mg/l) 0.043 0.472 0.063 0.284
Creatinine a (μmol/l) −0.061 0.234 0.037 0.470
a Variables not normally distributed are expressed as geometric
means with 95% CIs.
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Notwithstanding recent considerable progress in the complex
field of hepcidin assay [7], we still lack a gold reference
method [25], and each approach has relative advantages and
caveats. In particular, ELISA methods are cheaper, easy, and
have the potential for wide diffusion in clinical settings, but
lack absolute specificity for hepcidin isoforms because of
various degree of antibody cross-reactivity that is hard to
eliminate. On the other hand, MS-based methods are costly
and require dedicated personnel, but can properly distinguish
the isoforms. Indeed, in the only study published so far that
directly compared two second-generation hepcidin assays,
Kroot et al. showed that the observed differences in absolute
concentrations were explained, at least partially, by the
isoforms detected by MS, as opposed to “total” hepcidin
detected by ELISA [17]. Until now, data on hep-20 in healthy
subjects were limited and could only be inferred from small
case–control studies. We previously reported by SELDI-
TOF-MS that hep-20 was detectable in sera from 35 out of 57
(62%) healthy controls, at variance with CKD patients in
whom hep-20 was always detectable [15]. Kroot et al., using
WCX-TOF-MS assay, compared data from 23 healthy controls
with several groups of patients with heterogeneous disorders
of iron metabolism [17]. Hep-20 was not detectable in the few
of controls, but was frequently high in several diseases,
particularly in CKD. Different percentage in controls with
detectable hep-20 between the two studies may be explained
by the fact that we used more stringent criteria for “control”
definition, excluding subjects with even subclinical iron
deficiency and hence virtually eliminating those with low/
absent hepcidin production. Anyway, the present studyTable 5 – Predictors of hep-25:hep-20 ratio in males and
females.
Males Females
β-coefficient P β-coefficient P
Ferritin (μg/l) 0.504 <0.001 0.662 <0.001
Age (years) −0.147 0.001 −0.198 <0.001suggests that the relative contribute of hep-20 to “total”
serum hepcidin is not negligible at population level. In the
total population, mean hep-20 levels were about 14% of
corresponding hep-25 levels. On the other hand, when
considering only subjects with detectable hep-25 levels (n=
1405), this percentage rose up to 42.1%.
4.2. Hepcidin-20: more than simply a “fixed” degradation
products?
The presence of circulating truncated hepcidin isoforms raises
questions about their origin and biological meaning. Until
now, little is known about the processing of the 22-mer, and
20-mer peptides. Biochemical studies from Schranz and
co-workers [26] proposed that the two truncated isoforms
may result from the sequential action of unknown aminopep-
tidases on the mature hep-25 peptide. The Authors suggested
Dipeptidylpeptidase IV as a strong candidate for the genera-
tion of hep-20 fromhep-22, based on the presence of a proline
at the cleavage site [27].Whatever themolecularmechanism,
whether or not the processing is actively regulated remains
elusive. Theoretically, hep-20 may represent either the final
inactive product of constitutive (i.e. not regulated) degradationof
hep-25, or a possibly functional peptide whose production may
be modulated by body's need relative to the need of hep-25.
Clues to the latter hypothesis are the recent studies on the
05
10
15
20
25
<30 30-50 50-150 150-250 >250
Hep-20 Males
Hep-25 Males
Hep-20 Males
Hep-25 Males
H
ep
 le
ve
ls
 (n
mo
l/l)
0
5
10
15
20
25
H
ep
 le
ve
ls
 (n
mo
l/l)
* p < 0.001
*by ANOVA with polynomial contrasts for linear trend
35.6 %
11.1 %
9.6 %
9.1 %
7.6 %
Ferritin (ng/ml)
<30 30-50 50-150 150-250 >250
*by ANOVA with polynomial contrasts for linear trend
Ferritin (ng/ml)
23.1 % 
13.9 % 
10.0 % 
8.8 % 
9.0 % 
* p < 0.001
A
B
Fig. 5 – Relative percentages of hep-25 and hep-20 according
to increasing ferritin levels in males (A) and females (B),
respectively. The percentage value over the column
represents the proportion of hep-20 on total hep (calculated
as hep-20+hep-25).
34 J O U R N A L O F P R O T E O M I C S 7 6 ( 2 0 1 2 ) 2 8 – 3 5potentially relevant antimicrobial properties of hep-20 [10,11], as
well as the pilot studies on its increased concentration in several
diseases [12,13,15,16]. Although our study cannot inform on the
putative hep-20 function, it may point toward a putative active
regulation of hep-20 production and/or hep-25 degradation. This
is illustrated particularly by analyzing the hep-25:hep-20 ratio. A
simple degradation process should result in a relatively stable
ratio between the bioactive peptide (hep-25) and its catabolic
product (hep-20). On the other hand, as depicted in Fig. 4A and B,
the ratio was consistently lower in women during the fertile
period than in men of corresponding age, and increased
progressively in both sexes with increasing ferritin levels.
Accordingly, a multivariate model showed that ferritin was an
independent predictor of hep-20 in women with a negative
coefficient, and not positive as it would be expected if hep-20
would merely represent a constitutive degradation product of
hep-25 (Table 5). Taken together, these observations suggest that
in subjectswith irondeficiency the fewhep-25 producedmay be,
in addition, efficiently degraded to keep the iron bioactive
peptide as low as possible to maximize intestinal iron absorp-
tion. On the other hand, in subjects with adequate or high ironstatus hep-25 degradationmay proceed less efficiently to keep a
normal iron balance and/or prevent dangerous iron load.
4.3. Study limitations
Although fascinating, the hypothesis of an active regulation of
hep-20 needs further specific studies, being only indirectly
supported by our data. Other limitations of our study are
represented by the lack of mechanistic explanation on hep-20
formation/function, as well as the relatively high lower limit of
detection of our assay that did not allow proper evaluation of the
hep-25:hep-20 ratio in subjects with undetectable levels of both
isoforms. Moreover, our data suffer from the lack of standardiza-
tionof currenthepcidinassays [25], andneedconfirmationoncea
“gold reference” assay will be established.5. Conclusions
Considering the recent discovery of hepcidin, we are likely
only at the beginning of a story in which much has to be yet
discovered. While in the last decade we have learnedmuch on
hepcidin regulation at transcriptional level [1,2], times may be
mature for in depth investigations on the post-translational
regulation of this small peptide hormone. If confirmed, our
data may suggest an active regulation of hep-25 degradation
according to body iron need. The protease(s) responsible of
hep-25 processing, once identified, might be therapeutic
target(s) for the control of iron metabolism.Conflict of interest disclosure
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